MedPath

Dual Trigger Versus Booster Dose of HCG

Not Applicable
Completed
Conditions
Infertility
Interventions
Registration Number
NCT02397642
Lead Sponsor
Cairo University
Brief Summary

To salvage the luteal phase and improve pregnancy rate in antagonist IVF/ICSI cycles triggered with GnRH agonist. Two strategies are compared dual trigger with GnRH agonist plus 1000 IU of HCG or triggering with GnRH and giving a booster dose of HCG (1500 IU) on the day of ovum pickup.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
200
Inclusion Criteria
  • High responder females undergoing antagonist protocol IVF/ICSI cycle
  • More than 14 MII oocytes
  • Estradiol more than 3500 pg/ml on day of trigger
Exclusion Criteria
  • Any other protocol
  • Normal or poor responders

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Dual triggerIVF/ICSIGnRH agonist plus 1000 IU of HCG to trigger final maturation
Booster HCG doseIVF/ICSIGnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup
Dual triggerHuman Chorionic GonadotropinGnRH agonist plus 1000 IU of HCG to trigger final maturation
Booster HCG doseHuman Chorionic GonadotropinGnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup
Primary Outcome Measures
NameTimeMethod
Clinical pregnancy rate1 year

The number of cycles with a evidence of a gestational sac with fetal pulstaions after 5 weeks from pregnancy test

Secondary Outcome Measures
NameTimeMethod
OHSS rate1 year

The number of cycles with evidence of OHSS

Trial Locations

Locations (3)

Adam International hospital

🇪🇬

Giza, Egypt

Nile IVF center

🇪🇬

Giza, Egypt

IVF centre, Obstetrics and Gynaecology Department, Cairo University Hospitals (Kasr EL Aini)

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath